glp-1 receptor agonist and dpp-4 inhibitor combination not recommended GLP-1-RA inhibitors in the management of type 2 diabetes glp-1 receptor agonist and dpp-4

Description

Ready to explore GLP-1 options

First, we emulated two cardiovascular outcome trials, SUSTAIN-6 (semaglutide versus sitagliptin as placebo proxy) and SURPASS-CVOT (tirzepatide versus dulaglutide), to benchmark and critically evaluate our design, data and analytic framework

& Mucida, D

Natl Acad

No serious AEs were reported, followed by a 12-week washout period

therefore, although we have shown HbA1c and weight improvements in cohorts switching to semaglutide, these patients may have switched treatment for various reasons other than glycaemic control and weight loss